Not provided
Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 224842/Z/21/Z | Other Grant/Funding Number | Wellcome Trust | |
| 75A50122C00028 | Other Grant/Funding Number | HHS/BARDA OTA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biomedical Advanced Research and Development Authority | FED |
| Wellcome Trust | OTHER |
| German Federal Ministry of Education and Research | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples.
The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation in antibiotic for susceptible strains and not resistant strains.
Furthermore, this study will also add to our understanding on the performance of this test in various clinical specimens.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To determine the feasibility of performing antibiotic susceptibility testing (AST) for Neisseria gonorrhoeae directly from patient samples using InSignia workflow and assay against commonly used & clinically relevant antibiotics. | Feasibility of using the InSignia assay to determine the antibiotic susceptibility of NG - from sample collection, handling & transport to laboratory analysis & data interpretation. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| To study the performance of the InSignia assay in determining antibiotic susceptibility of NG against commonly used & clinically relevant agents in clinical samples with comparison to gold standard methods. | NG antibiotic susceptibility profile as determined by the InSignia assay compared to two other methods of NG AST - conventional culture via disc diffusion testing & E-test and genetic resistance testing via the ResistancePlus® GC (RPGC) IVD test (TGA, CE-IVD (IVDR) approved), developed by SpeeDx Pty Ltd. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients presenting with confirmed NG infections in one or both of the following anatomical sites: the urethra & the rectum.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nicole Lima | Contact | +61 0292094170 | nicolel@speedx.com.au |
Not provided
Not provided
Not provided
| Australian Research Council Research Hub to Combat Antimicrobial Resistance |
| UNKNOWN |
Not provided
Not provided
Not provided
| 1 year |
| ID | Term |
|---|---|
| D004194 | Disease |
| D006069 | Gonorrhea |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D016870 | Neisseriaceae Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided